Shandong Keyuan Pharmaceutical Co. Ltd. A (301281) — Working Capital to Net Assets Ratio
Shandong Keyuan Pharmaceutical Co. Ltd. A (301281) has a Working Capital to Net Assets ratio of 40.2% as of June 2025. Working capital of CN¥555.85 Million (current assets of CN¥655.92 Million minus current liabilities of CN¥100.07 Million) is measured against net assets of CN¥1.38 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Shandong Keyuan Pharmaceutical Co. Ltd. leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Shandong Keyuan Pharmaceutical Co. Ltd. A Working Capital to Net Assets (2021–2024)
This chart shows how Shandong Keyuan Pharmaceutical Co. Ltd. A's Working Capital to Net Assets ratio has evolved across 4 annual periods from 2021 to 2024. As of June 2025, the ratio stands at 40.2%, reflecting working capital of CN¥555.85 Million against net assets of CN¥1.38 Billion CNY. See Shandong Keyuan Pharmaceutical Co. Ltd. (301281) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Shandong Keyuan Pharmaceutical Co. Ltd. A (2021–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Shandong Keyuan Pharmaceutical Co. Ltd. A from 2021 to 2024, covering 4 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Shandong Keyuan Pharmaceutical Co. Ltd. stock valuation.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 42.0% | CN¥570.95 Million | CN¥1.36 Billion | CN¥690.73 Million | CN¥119.78 Million | ▼ -15.7 pp |
| 2023 | 57.7% | CN¥767.65 Million | CN¥1.33 Billion | CN¥878.79 Million | CN¥111.14 Million | ▲ +24.1 pp |
| 2022 | 33.6% | CN¥174.40 Million | CN¥519.73 Million | CN¥282.27 Million | CN¥107.86 Million | ▲ +12.1 pp |
| 2021 | 21.5% | CN¥92.64 Million | CN¥430.98 Million | CN¥203.38 Million | CN¥110.75 Million | — |